Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chicory root extract is a botanical drug candidate developed by Phytomedics Inc. for the treatment of osteoarthritis. Derived from the roots of *Cichorium intybus*, this specific hydrocarbon extract contains bioactive compounds, primarily sesquiterpene lactones, which are believed to possess significant anti-inflammatory properties. The drug's mechanism of action involves the inhibition of pro-inflammatory mediators and enzymes, such as cyclooxygenase-2 (COX-2) and various cytokines, which contribute to joint inflammation and pain. A Phase 1 clinical trial (NCT00247156) was conducted to evaluate the safety, tolerability, and preliminary efficacy of escalating doses of the extract in patients over 50 years of age with osteoarthritis of the hip or knee. Although the Phase 1 results showed a trend toward symptomatic improvement, no further clinical development has been reported, and the product is considered discontinued.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chicory root extract.